Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Cystic Fibrosis (Jul 2017)

Posted by Matt Breese on Jul 31, 2017

Find me on:

According to our recent payer coverage analysis for CF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for payer pharmacy benefit formularies reveals an increase in restricted lives covered under commercial plans. In contrast, health exchange and medicare formularies experienced a slightly favorable shift towards unrestricted coverage and the overall "restrictiveness" of PA and step edit policies remained stable.

mmit-reality-check-cysticfibrosis-q3.png

Source: MMIT data as of Q3 2017

Trends: Over recent years, the CF landscape received an injection of new treatments that increased the utilization of specialty pharmacy networks. A recent study reveals that CF patient adherence is extremely low, which is triggering a greater investment in understanding why. Organizations like the Cystic Fibrosis Foundation provide patients and prescribers with well-needed resources that create a strong support network.

To read the full Reality Check on cystic fibrosis with key findings on clinical characteristics, CF drug market access and payer coverage, please click on the thumbnail below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Branding & Marketing